Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Safety and Efficacy of CRISPR-Based Genome Editing for Neovascular AMD
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2023
Episode 1: Review of the Clarity Study with Dr. Amin Kherani
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD
Raj K. Maturi, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more